Hematology 2026_ Event Postponement
This is to inform that due to some circumstances beyond the organizer control, "2nd Edition of International Summit on Hematology and Blood Disorders" (Hematology 2026) October 08 -10, 2026 | Tokyo, Japan has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at hematology@magnusconference.com or call + 1 (702) 988 2320.
2nd Edition of International Summit on Hematology and Blood Disorders
October 8-10, 2026
Minimal Residual Disease
Minimal residual disease refers to the small number of malignant cells that remain after treatment and may lead to disease relapse. Sensitive detection methods have made minimal residual disease assessment a powerful prognostic tool in hematologic malignancies. Techniques include flow cytometry, molecular assays, and sequencing-based approaches. Monitoring minimal residual disease enables early intervention and treatment optimization. Its role in guiding therapy intensity and duration is expanding across multiple hematologic diseases. Ongoing research aims to standardize assessment methods and integrate minimal residual disease into routine clinical decision-making.
Submit your abstract Today
Title : Acute intermittent porphyria: A neurological dilemma obscured by ubiquitous gastrointestinal presentation
Mayank Anand Singh, Mimer Medical College, India
Title : Comprehensive symptom management and supportive nursing care in a preterm toddler undergoing HSCT for pyruvate kinase deficiency
Tran Thi Dung, Vinmec International Hospital, Vietnam
Title : Enhancing Thalassemia Gene Carrier Identification in Non-anemic Populations Using AI Erythrocyte Morphology Analysis and Machine Learning
Junxun Li, First Affiliated Hospital, Sun Yat-sen University, China
Title : Predictive Value of Routine Laboratory Tests for Early Death in Pediatric Hemophagocytic Lymphohistiocytosis Patients
Junxun Li, First Affiliated Hospital, Sun Yat-sen University, China
Title : Eltrombopag added to combined immunosuppressive therapy IST in children with acquired severe aplastic anemia accelerates hematologic recovery and should be continued in the second course of IST
Olga Goronkova, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology , Russian Federation
Title : Arsenic Trioxide and Its Applications
Peng Zhang, Chief physician, China